The latest price target for Hims & Hers Health (NYSE:HIMS) was reported by B of A Securities on April 16, 2026. The analyst firm set a price target for $25.00 expecting HIMS to fall to within 12 months (a possible -17.19% downside). 38 analyst firms have reported ratings in the last year.

The latest analyst rating for Hims & Hers Health (NYSE:HIMS) was provided by B of A Securities, and Hims & Hers Health maintained their neutral rating.

The last upgrade for Hims & Hers Health Inc happened on March 10, 2026 when Citigroup raised their price target to $24. Citigroup previously had a sell for Hims & Hers Health Inc.

The last downgrade for Hims & Hers Health Inc happened on February 24, 2026 when BTIG changed their price target from N/A to N/A for Hims & Hers Health Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Hims & Hers Health, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Hims & Hers Health was filed on April 16, 2026 so you should expect the next rating to be made available sometime around April 16, 2027.

While ratings are subjective and will change, the latest Hims & Hers Health (HIMS) rating was a maintained with a price target of $21.00 to $25.00. The current price Hims & Hers Health (HIMS) is trading at is $30.19, which is out of the analyst’s predicted range.